Lipocine logo

LipocineNASDAQ: LPCN

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

22 October 2013

Next earnings report:

08 November 2024

Last dividends:

N/A

Next dividends:

N/A
$28.99 M
-82%vs. 3y high
28%vs. sector
-vs. 3y high
-vs. sector
-61%vs. 3y high
47%vs. sector
-99%vs. 3y high
65%vs. sector

Price

regular market | Wed, 30 Oct 2024 13:30:00 GMT
$5.42-$0.15(-2.69%)

Dividend

No data over the past 3 years
$89.60 K$150.00 K
$89.60 K-$3.07 M

Analysts recommendations

Institutional Ownership

LPCN Latest News

Lipocine Announces Phase 2 Data on LPCN 2401 to be Presented at ObesityWeek®
prnewswire.com05 September 2024 Sentiment: POSITIVE

Study evaluated LPCN 2401 in participants with obesity (BMI ≥30) and participants with BMI ≥27 with at least one weight-related comorbidity SALT LAKE CITY , Sept. 5, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced that a poster featuring Phase 2 data on LPCN 2401 will be presented at the Obesity Society's Annual ObesityWeek® conference to be held November 3 – 6, 2024 in San Antonio, TX.

Lipocine to Present at the H.C. Wainwright Annual NASH Investor Conference
PRNewsWire23 October 2023 Sentiment: POSITIVE

SALT LAKE CITY , Oct. 23, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced that it will present and meet with investors at the H.C. Wainwright 7th Annual NASH Investor Conference, taking place virtually October 24, 2023.

Why Is Lipocine (LPCN) Stock Up 32% Today?
InvestorPlace27 July 2023 Sentiment: POSITIVE

Lipocine (NASDAQ: LPCN ) stock is rising higher on Thursday after the company released positive results from a Phase 2 clinical trial. That trail covers the use of LPCN 1148 as a treatment for patients suffering from cirrhosis.

What type of business is Lipocine?

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.

What sector is Lipocine in?

Lipocine is in the Healthcare sector

What industry is Lipocine in?

Lipocine is in the Biotechnology industry

What country is Lipocine from?

Lipocine is headquartered in United States

When did Lipocine go public?

Lipocine initial public offering (IPO) was on 22 October 2013

What is Lipocine website?

https://www.lipocine.com

Is Lipocine in the S&P 500?

No, Lipocine is not included in the S&P 500 index

Is Lipocine in the NASDAQ 100?

No, Lipocine is not included in the NASDAQ 100 index

Is Lipocine in the Dow Jones?

No, Lipocine is not included in the Dow Jones index

When was Lipocine the previous earnings report?

No data

When does Lipocine earnings report?

The next expected earnings date for Lipocine is 08 November 2024